Clinical trials: SGLT 2 Inhibitors
Diabetes Mellitus, Type 2
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes.
- Trial name
- NCT03922750
- Testing
- Insulin icodec, Insulin glargine U100
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 154 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of IBI362 in Participants With Type 2 Diabetes
This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.
- Trial name
- NCT05606913
- Testing
- dulaglutide, IBI362
- Where
- China
- Volunteers
- 731 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.
- Trial name
- NCT01413204
- Testing
- TA-7284 Low, TA-7284 High
- Where
- 5 sites in Japan
- Volunteers
- 272 people
- Sponsor
- Tanabe Pharma Corporation
Asymptomatic Hyperuricemia
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat +…
- Trial name
- NCT03316131
- Testing
- Verinurad, Febuxostat, Dapagliflozin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Metformin Monotherapy or in Combination with…
- Trial name
- Optimum 2 (NCT06778967)
- Testing
- GZR18, semaglutide
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus, Type 2
Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
The purpose of the study is to estimate the incidence of below-knee lower extremity amputation in type 2 diabetes mellitus (T2DM) participants newly exposed to sodium-glucose co-transporter 2 inhibitors (SGLT2i)/ non-SGLT2i…
- Trial name
- NCT02857764
- Volunteers
- 127,690 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.
- Trial name
- STELLA-ELDER (NCT02297620)
- Testing
- Suglat®
- Where
- 8 sites in Japan
- Volunteers
- 8,687 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus Type 2
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus…
- Trial name
- CVD-REAL (NCT02993614)
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 99,999 people
- Sponsor
- AstraZeneca
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Type 2 Diabetes Mellitus
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT01022112
- Testing
- TA-7284-Low, TA-7284-Low-middle, TA-7284-High-middle
- Where
- 6 sites in Japan
- Volunteers
- 383 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
- Trial name
- AWARD-10 (NCT02597049)
- Testing
- Dulaglutide, SGLT2 inhibitor, Metformin
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Phase 3 Study of HS-20094 in Patients With T2DM
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors…
- Trial name
- NCT07156539
- Testing
- HS-20094 Injection, Dulaglutide Injection
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes Mellitus
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore
To evaluate clinical effectiveness and safety of Singaporean Type 2 Diabetes mellitus patients administered SGLT 2 inhibitor monotherapy or in combination with other commonly used hypoglycaemic drugs in real life clinical…
- Trial name
- NCT02578563
- Where
- Singapore
- Volunteers
- 201 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (ie, blood levels of JNJ-28431754) and pharmacodynamics (ie, urine and blood levels of glucose) of JNJ-28431754 compared to placebo in patients…
- Trial name
- NCT00963768
- Testing
- JNJ 28431754
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2…
- Trial name
- NCT06688123
- Testing
- SHR-3167, Insulin glargine
- Where
- 2 sites in China
- Volunteers
- 275 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to assess the efficacy (superiority to placebo) of ipragliflozin based on the changes in HbA1C, as well as its safety, in patients with type 2 diabetes mellitus in combination with an insulin…
- Trial name
- NCT02175784
- Testing
- ipragliflozin
- Where
- 8 sites in Japan
- Volunteers
- 262 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 2
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
A prospective multi-centre, open-label, two arm, parallel design, superiority, pragmatic, randomised controlled trial, over an 8-month period.
- Trial name
- NCT05944432
- Testing
- FreeStyle Libre 3 Continuous Glucose Monitoring System., Self monitoring of blood glucose
- Where
- 25 sites in United Kingdom
- Volunteers
- 469 people
- Sponsor
- Abbott Diabetes Care
Type 2 Diabetes
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets
- Trial name
- STELLALONGTERM (NCT02479399)
- Testing
- ipragliflozin
- Where
- 8 sites in Japan
- Volunteers
- 11,412 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient…
- Trial name
- COMETA (NCT03267576)
- Testing
- Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin
- Where
- 5 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC